Valuation: Arcus Biosciences, Inc.

Market Cap 381.47Cr 333.33Cr 306.09Cr 285.45Cr 541.14Cr 36TCr 550.27Cr 3.69TCr 1.43TCr 18TCr 1.43TCr 1.4TCr 61TCr P/E 2026 *
-8.25x
P/E 2027 * -8.99x
Enterprise Value 319.34Cr 279.04Cr 256.23Cr 238.95Cr 453Cr 30TCr 460.64Cr 3.09TCr 1.2TCr 15TCr 1.2TCr 1.17TCr 51TCr EV / Sales 2026 *
37.5x
EV / Sales 2027 * 38.2x
Free-Float
70.85%
Yield 2026 *
-
Yield 2027 * -
1 day+4.88%
1 week+0.26%
Current month-1.62%
1 month+23.95%
3 months+32.10%
6 months+30.23%
Current year+27.28%
1 week 28.78
Extreme 28.775
31.74
1 month 21.84
Extreme 21.84
31.74
Current year 18.52
Extreme 18.515
31.74
1 year 8.03
Extreme 8.03
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 01/05/2015
Chief Executive Officer 67 01/05/2015
Director of Finance/CFO 53 01/08/2020
Director TitleAgeSince
Chairman 67 01/12/2017
Director/Board Member 65 18/09/2017
Director/Board Member 71 01/05/2015
Date Insider Type Main position Quantity % Market Cap.
24/06Sell

Founder

-6,431 0.0051%
11/06Free

Director

22,600 0.0180%
11/06Free

Director

22,600 0.0180%
Change 5-day change 1-year change 3-year change Capi.($)
+4.88%+0.26%+253.08%+49.34% 381.47Cr
+1.15%+6.73%+2.48%+7.78% 4.91TCr
+0.92%+6.21%+408.85%+607.44% 4.02TCr
+1.89%+11.06%+25.75%-7.89% 3.46TCr
+5.46%+8.10%+21.83%+66.94% 3.31TCr
+1.20%+2.02%+9.79%+32.43% 2.52TCr
+2.51%+4.94% - - 1.7TCr
+2.58%+7.24%+71.03%+132.17% 1.59TCr
+0.14%+0.35%+13.41%+18.82% 1.38TCr
-1.14%+7.52%+14.75%-30.83% 1.33TCr
Average +1.67%+4.22%+91.22%+97.36% 2.46TCr
Weighted average by Cap. +1.49%+5.22%+91.28%+129.78%

Financials

2026 *2027 *
Net sales 8.51Cr 7.43Cr 6.83Cr 6.36Cr 12Cr 809.78Cr 12Cr 82Cr 32Cr 397.19Cr 32Cr 31Cr 1.37TCr 9.31Cr 8.13Cr 7.47Cr 6.96Cr 13Cr 885.91Cr 13Cr 90Cr 35Cr 434.53Cr 35Cr 34Cr 1.5TCr
Net income -46Cr -40Cr -37Cr -34Cr -65Cr -4.34TCr -66Cr -440.91Cr -170.87Cr -2.13TCr -171.36Cr -167.64Cr -7.34TCr -43Cr -38Cr -35Cr -32Cr -61Cr -4.1TCr -62Cr -415.94Cr -161.19Cr -2.01TCr -161.66Cr -158.14Cr -6.93TCr
Net Debt -62Cr -54Cr -50Cr -46Cr -88Cr -5.92TCr -90Cr -600.27Cr -232.63Cr -2.9TCr -233.3Cr -228.23Cr -10TCr -26Cr -23Cr -21Cr -19Cr -37Cr -2.47TCr -37Cr -250.56Cr -97Cr -1.21TCr -97Cr -95Cr -4.17TCr
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
02/26/02 $30.33 +4.88% 13,25,784
01/26/01 $28.92 -6.20% 16,64,831
30/26/30 $30.83 -0.80% 13,44,884
29/26/29 $31.08 +0.26% 15,65,332
26/26/26 $31.00 +2.48% 43,52,591
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
30.33USD
Average target price
35.75USD
Spread / Average Target
+17.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock